Eli Lilly licensed exclusive rights for AK1780 from Asahi Kasei Pharma, an orally bioavailable P2X7 receptor antagonist that completed Phase 1 dose and clinical pharmacology studies. Lilly paid $20M upfront with up to $210M in potential development and regulatory milestones.